Literature DB >> 17269894

Time-dependent CYP inhibition.

Robert J Riley1, Ken Grime, Richard Weaver.   

Abstract

Time-dependent inhibition (TDI) of CYP refers to a change in potency during an in vitro incubation or dosing period in vivo. Potential mechanisms include the formation of inhibitory metabolites and mechanism-based inhibition (MBI). In vitro experiments are configured to assess TDI and MBI is inferred, at least initially. MBI is more profound after multiple-dosing and the recovery period is independent of continued drug exposure. Advances in in vitro-in vivo extrapolations for competitive inhibition and the potential relationship between MBI and reactive metabolite-mediated toxicity, have redirected emphasis to CYP TDI. In contrast, with reversible inhibition, strategies for projecting the risks from TDI are less developed and the traditional I/K(i) model often yields a dramatic underprediction. This review explores the contribution of TDI to drug-drug interactions and idiosyncratic drug toxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17269894     DOI: 10.1517/17425255.3.1.51

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  13 in total

1.  Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.

Authors:  Jane R Kenny; Sophie Mukadam; Chenghong Zhang; Suzanne Tay; Carol Collins; Aleksandra Galetin; S Cyrus Khojasteh
Journal:  Pharm Res       Date:  2012-03-14       Impact factor: 4.200

Review 2.  In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.

Authors:  Stephen Fowler; Hongjian Zhang
Journal:  AAPS J       Date:  2008-08-07       Impact factor: 4.009

Review 3.  Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

Authors:  Yue-Zhong Shu; Benjamin M Johnson; Tian J Yang
Journal:  AAPS J       Date:  2008-03-13       Impact factor: 4.009

Review 4.  Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.

Authors:  Han Kiat Ho; James Chun Yip Chan; Klarissa D Hardy; Eric Chun Yong Chan
Journal:  Drug Metab Rev       Date:  2015-02-02       Impact factor: 4.518

5.  In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.

Authors:  Thomas M Polasek; Janani S Sadagopal; David J Elliot; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2009-12-11       Impact factor: 2.953

6.  Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System.

Authors:  Xiaojing Wang; Minghua Sun; Connie New; Spencer Nam; Wesley P Blackaby; Alastair J Hodges; David Nash; Mizio Matteucci; Joseph P Lyssikatos; Peter W Fan; Suzanne Tay; Jae H Chang
Journal:  ACS Med Chem Lett       Date:  2015-07-12       Impact factor: 4.345

7.  Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection.

Authors:  J Matthew Hutzler; Larissa M Balogh; Michael Zientek; Vikas Kumar; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2008-10-06       Impact factor: 3.922

8.  Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy via screening of a natural product repository.

Authors:  Prashant Joshi; Vinay R Sonawane; Ibidapo S Williams; Glen J P McCann; Linda Gatchie; Rajni Sharma; Naresh Satti; Bhabatosh Chaudhuri; Sandip B Bharate
Journal:  Medchemcomm       Date:  2018-01-08       Impact factor: 3.597

9.  Evaluation of drug interaction potential of Labisia pumila (Kacip Fatimah) and its constituents.

Authors:  Vamshi K Manda; Olivia R Dale; Charles Awortwe; Zulfiqar Ali; Ikhlas A Khan; Larry A Walker; Shabana I Khan
Journal:  Front Pharmacol       Date:  2014-08-08       Impact factor: 5.810

10.  Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.

Authors:  Ryan C Schoenfeld; David L Bourdet; Ken A Brameld; Elbert Chin; Javier de Vicente; Amy Fung; Seth F Harris; Eun K Lee; Sophie Le Pogam; Vincent Leveque; Jim Li; Alfred S-T Lui; Isabel Najera; Sonal Rajyaguru; Michael Sangi; Sandra Steiner; Francisco X Talamas; Joshua P Taygerly; Junping Zhao
Journal:  J Med Chem       Date:  2013-10-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.